Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Notes Payables (2016 - 2023)

Historic Notes Payables for Ocular Therapeutix (OCUL) over the last 9 years, with Q2 2023 value amounting to $2.1 million.

  • Ocular Therapeutix's Notes Payables changed N/A to $2.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2020, which is N/A changed from last year.
  • Per Ocular Therapeutix's latest filing, its Notes Payables stood at $2.1 million for Q2 2023.
  • In the past 5 years, Ocular Therapeutix's Notes Payables registered a high of $8.3 million during Q4 2020, and its lowest value of $2.1 million during Q1 2020.
  • In the last 3 years, Ocular Therapeutix's Notes Payables had a median value of $5.2 million in 2020 and averaged $5.2 million.
  • Within the past 5 years, the most significant YoY rise in Ocular Therapeutix's Notes Payables was 29971.07% (2021), while the steepest drop was 29971.07% (2021).
  • Quarter analysis of 3 years shows Ocular Therapeutix's Notes Payables stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then crashed by 74.87% to $2.1 million in 2023.
  • Its Notes Payables was $2.1 million in Q2 2023, compared to $8.3 million in Q1 2021 and $8.3 million in Q4 2020.